Hypertension Diagnostics is focused on the development of proprietary cardiovascular profiling technology that analyzes arterial pulse pressure waveform data. HDI has developed two models of it's HDI/PulseWave CardioVascular Profiling Instrument. HDI's first model, the HDI/PulseWave CR-2000, is currently in use by physician scientists for researchpurposes only. The second model, the HDI/PulseWave DO-2020, is intended to assist physicians in screening and diagnosing patients with cardiovascular disease. (PRESS RELEASE)
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | -- |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | -- |
| Free Float | -- |
| Market Capitalization | -- |
| Average Volume (Last 20 Days) | 10.00 |
| Beta (Past 60 Months) | -0.75 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 40.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |